Routine

Antimicrobial stewardship & common empiric regimens by source

Infection · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A systematic approach to optimising antimicrobial use to improve outcomes and curb resistance, pairing stewardship principles with source-directed empirical regimens guided by local resistance.

Red flags

  • Involve microbiology/ID for resistant or unusual organisms, treatment failure, OPAT/complex IV therapy, prosthetic/device infection, and penicillin-allergy delabelling
  • Escalate per local sepsis pathway; admission is driven by the underlying infection's severity

Assessment

Investigations

  • Guide therapy with cultures and sensitivities, Gram stain, the local antibiogram and biomarkers (procalcitonin can support stopping)
  • Confirm the source and organism rather than treating colonisation (e.g. asymptomatic bacteriuria)
  • Document indication, review date and planned duration on the drug chart

Management

  • Empirical regimens by source (adjust to local policy/resistance): CAP - amoxicillin or co- amoxiclav +/- macrolide (CURB-65 guides severity)
  • HAP/VAP - antipseudomonal beta- lactam (e.g. piperacillin-tazobactam)
  • Complicated UTI/pyelonephritis - co-amoxiclav or cephalosporin/gentamicin
  • Intra-abdominal - piperacillin-tazobactam or a cephalosporin plus metronidazole, with source control
  • Cellulitis - flucloxacillin
  • Meningitis - ceftriaxone (+ amoxicillin if Listeria risk, + dexamethasone)
  • Neutropenic sepsis - piperacillin-tazobactam promptly
  • Escalate to carbapenems only where resistance dictates

Disposition

Involve microbiology/ID for resistant or unusual organisms, treatment failure, OPAT/complex IV therapy, prosthetic/device infection, and penicillin-allergy delabelling.

Complications & pitfalls

  • Of poor stewardship: multidrug-resistant infection, Clostridioides difficile colitis, drug toxicity (nephrotoxicity, QT prolongation), candidaemia, and treatment failure
  • Under- treatment of severe sepsis also harms, so balance is key

Exam pearls

  • Start smart, then focus: take cultures, give prompt empirical cover in sepsis, and review at 48-72 hours to de-escalate, switch to oral and stop; the shortest effective course is usually best.
  • Monitoring & follow-up: Reassess at 48-72 h for de-escalation and IV-to-oral switch; monitor renal function and drug levels where needed (vancomycin, aminoglycosides) and watch for C. difficile. Audit prescribing against policy, feed back to prescribers, and set the shortest effective course (shorter durations now favoured for many infections).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.